ライフサイエンスコーパス: oncofetal

1 eric immune receptors (CR) against human 5T4 oncofetal Ag (h5T4) and evaluated their tumor therapeuti

2 Oncofetal Ag (OFA) is a 44-kDa glycoprotein expressed du

3 alpha-Fetoprotein (AFP) is an oncofetal Ag and has intrinsic immunoregulatory properti

4 alpha-fetoprotein (AFP) is an oncofetal Ag that is highly expressed in abnormalities o

5 During tumor development in mice and humans, oncofetal Ag/immature laminin receptor (OFA/iLRP)-specif

6 r metabolism, endocrine status, hypoxia, and oncofetal and differentiation antigens.

7 The oncofetal antigen 5T4 is expressed in more than 90% of c

8 ese novel observations demonstrate that this oncofetal antigen can serve as an effective tumor reject

9 acid (Neu5Gc), which was long considered an oncofetal antigen in humans.

10 This oncofetal antigen is also expressed by hepatocytes in ce

11 Lex is an oncofetal antigen which appears on human gastric epithel

12 deaminated sialic acids KDN (2), a potential oncofetal antigen, and N-acetylneuraminic acid (Neu5Ac,

13 telomerase reverse transcriptase, G250, and oncofetal antigen, but not against self-antigens express

14 N-Glycolyneuraminic acid, a human oncofetal antigen, was found at all sites of all three c

15 ssessing the Lewisx determinant, which is an oncofetal antigen.

16 The amplified cells produce sialylated oncofetal carbohydrate antigens that function as recepto

17 The peptides encoded by the rat liver oncofetal cDNA TA1 and the human lymphocyte activation g

18 sis with one of these products confirmed the oncofetal expression of transcripts related to TuAg.1/pE

19 The oncofetal fibronectin (B-FN) isoform is present in vesse

20 paid to the deposit of collagen, we identify oncofetal fibronectin (FN) as a major and obligate compo

21 ) TGF-beta treatment caused up-regulation of oncofetal fibronectin (onfFN), which is defined by mAb F

22 ROR1 has characteristics of an oncofetal gene and is expressed in undifferentiated embr

23 This bivalent epigenetic control of oncofetal gene expression in cancer cells may offer nove

24 The oncofetal gene SALL4, a marker of a subtype of hepatocel

25 development, suggesting that let-7-regulated oncofetal genes (LOG) may become reexpressed in cancer c

26 ion embryonic program that encompasses known oncofetal genes as well as oncogenes not previously asso

27 ncovers a miRNA-repressed network containing oncofetal genes Imp1, Imp2, and Imp3 (Imp1-3) that is up

28 subgroup of hHCCs, with shared activation of oncofetal genes including Igf2, correlating with CpG hyp

29 -expression of ductal progenitor markers and oncofetal genes.

30 Polysialic acid is an oncofetal glycopolymer, added to the glycans of a small

31 Human carcinoembryonic antigen (CEA) is an oncofetal glycoprotein overexpression of which by gastro

32 ryonic antigen (CEA) is a well-characterized oncofetal glycoprotein whose overexpression by human car

33 The recognition of oncofetal H type 1 and type 1 LacNAc on OC by mAb-A4 is

34 tures of maturing hepatocytes expressing the oncofetal marker, alpha-fetoprotein.

35 We show that the oncofetal protein 5T4 is expressed on tumor-initiating c

36 r the diagnosis and management of HCC, is an oncofetal protein expressed in a majority of HCCs but ra

37 Gamma-globin, an oncofetal protein overexpressed by clonogenic JMML cells

38 The RNA-binding protein IMP-3 is an oncofetal protein overexpressed in many human malignanci

39 The multiple functions of the oncofetal protein survivin are dependent on its selectiv

40 actor 2 mRNA-binding protein-1 (IMP-1) is an oncofetal protein that binds directly to and stabilizes

41 SALL4 is an oncofetal protein that is expressed in the human fetal l

42 e type 3 iodothyronine deiodinase (D3) is an oncofetal protein that is rarely expressed in adult life

43 RBMY is a novel oncofetal protein that plays a key role in attenuating g

44 rowth factor-2 mRNA binding protein 3) is an oncofetal protein whose expression is prognostic for poo

45 This localization requires the oncofetal protein ZBP1 (Zipcode binding protein 1), whic

46 CRD-BP also appears to be an oncofetal protein, based upon its expression during mamm

47 Thus, IMP-3 is considered to be an oncofetal protein.

48 ancer cases, and the CRD-BP appears to be an oncofetal protein.

49 transformed cell lines suggests CRD-BP is an oncofetal protein.

50 pression; and high coordinated expression of oncofetal proteins and stem-cell markers, while low-risk

51 We aimed to investigate whether IMP3, an oncofetal RNA-binding protein, can be used as a biomarke

52 lted from neonatal-specific expression of an oncofetal RNA-binding protein, IGF2BP3, which prevented

53 GF2 mRNA through phosphorylation of IMP2, an oncofetal RNA-binding protein.

54 ing proteins (IGF2BPs), are highly conserved oncofetal RNA-binding proteins (RBPs) that regulate RNA

55 CRD-BP/IGF2BP1 has been characterized as an "oncofetal" RNA binding protein typically highly expresse

56 Similarly, we found that normal and oncofetal splice variants of fibronectin, the primary EC

57 break immune tolerance to ROR1, which is an oncofetal surface antigen and survival-signaling recepto

58 ithelial cells that express MUC1 bearing the oncofetal Thomsen-Friedenreich antigen (Galbeta1,3 GalNA